Dataset Information


Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).

ABSTRACT: INTRODUCTION:Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBV+) or human herpesvirus-8-positive (HHV-8+) tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). PATIENTS AND METHODS:We performed a phase I trial of VOR given with R-based infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) (n = 12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule. VOR (300 or 400 mg) was given orally on days 1 to 5 with each cycle of R-EPOCH for 10 high-risk patients with diffuse large B-cell lymphoma (1 EBV+), 1 EBV+/HHV-8+ primary effusion lymphoma, and 1 unclassifiable NHL. VOR was escalated from 300 to 400 mg using a standard 3 + 3 design based on dose-limiting toxicity observed in cycle 1 of R-EPOCH. RESULTS:The recommended phase II dose of VOR was 300 mg, with dose-limiting toxicity in 2 of 6 patients at 400 mg (grade 4 thrombocytopenia, grade 4 neutropenia), and 1 of 6 treated at 300 mg (grade 4 sepsis from tooth abscess). Neither VOR, nor cART regimen, significantly altered chemotherapy steady-state concentrations. VOR chemotherapy did not negatively impact CD4+ cell counts or HIV viral loads, which decreased or remained undetectable in most patients during treatment. The response rate in high-risk patients with NHL treated with VOR(R)-EPOCH was 100% (complete 83% and partial 17%) with a 1-year event-free survival of 83% (95% confidence interval, 51.6%-97.9%). CONCLUSION:VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL.

PROVIDER: S-EPMC6697160 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5962410 | BioStudies
2020-01-01 | S-EPMC7556212 | BioStudies
2010-01-01 | S-EPMC2858478 | BioStudies
2019-01-01 | S-EPMC6328036 | BioStudies
2012-01-01 | S-EPMC3310940 | BioStudies
2013-01-01 | S-EPMC3547779 | BioStudies
2015-01-01 | S-EPMC4405278 | BioStudies
2019-01-01 | S-EPMC6473267 | BioStudies
2010-01-01 | S-EPMC5665679 | BioStudies
2010-01-01 | S-EPMC3950937 | BioStudies